Pharmerica (PMC) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts PMC Hot Sheet
Join SI Premium – FREE
Pharmerica (NYSE: PMC) reported Q2 EPS of $0.37, $0.04 better than the analyst estimate of $0.33. Revenue for the quarter came in at $497 million versus the consensus estimate of $491.66 million.
Pharmerica sees FY2015 EPS of $1.55-$1.65, versus the consensus of $1.63. Pharmerica sees FY2015 revenue of $1.95-2.05 billion, versus the consensus of $2.03 billion.
For earnings history and earnings-related data on Pharmerica (PMC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- InnovAge (INNV) Tops Q1 EPS by 6c; Offers Guidance
- LTC Properties (LTC) Tops Q3 EPS by 22c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
